Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

S-488410

In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).

Trial Locations (1)

520-2192

Department of Medical Oncology, Shiga University of Medical Science Hospital, Ōtsu

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Showa University

OTHER

collaborator

Fukushima Medical University

OTHER

collaborator

Tohoku University

OTHER

collaborator

Shionogi

INDUSTRY

collaborator

Tokyo University

OTHER

collaborator

University of Chicago

OTHER

lead

Shiga University

OTHER